Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Fruit Fly Alcohol Tolerance Investigated and Explained

Kristi Montooth, an associate professor in the University of Nebraska School of Biological Sciences, displays a bottle containing fruit flies that are the subject of her research. She is a co-author of a new scientific paper investigating the evolutionary caus

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Kristi Montooth, an associate professor in the University of Nebraska School of Biological Sciences, displays a bottle containing fruit flies that are the subject of her research. She is a co-author of a new scientific paper investigating the evolutionary causes of fruit flies’ tolerance for alcohol. [Craig Chandler/University Communication, University of Nebraska-Lincoln]

The common fruit fly, Drosophila melanogaster, has evolved to have an impressive tolerance for alcohol, according to scientists. More than two decades ago, in one of the first papers using gene sequences to find signatures of natural selection, investigators hypothesized that a molecular change in an enzyme gave the fly species its superior ability to metabolize alcohol. Scientists concluded that the change they found in the alcohol dehydrogenase (ADH) protein could be the adaptation that allowed D. melanogaster to colonize ethanol-rich habitats in rotting fruit better than its nearly identical relative Drosophila simulans.

It seemed a logical conclusion that the gene sequence changes that altered amino acids in an enzyme that breaks down alcohol would be the mechanism of natural selection. However, the authors of a new paper (“Experimental Test and Refutation of a Cassic Case of Molecular Adaptation in Drosophila melanogaster”) published online in Nature Ecology & Evolution say they have now refuted that hypothesis. Their findings indicate that intuition and signatures of selection in gene sequence may not be enough for scientists to conclusively solve the puzzles of molecular evolution. Tests also are needed to check how the changes function in organisms.

Using genetic engineering, researchers resurrected the fruit flies' ADH protein from ancestral species to compare whether the amino acid changes that have occurred in D. melanogaster's ADH enzyme actually improved the fruit flies' ability to tolerate alcohol. The answer, conclusively, was “no.”

“This paper takes advantage of modern molecular biology and genetic approaches to test some of those hypotheses,” said University of Nebraska, Lincoln biologist Kristi L. Montooth, Ph.D., a fruit fly expert who co-authored the new study. “It doesn't dispute that this species has a high ethanol tolerance. But it suggests that the molecular changes that have led to that high tolerance are not in this protein. They must be in other genes in the genome.”

The search for new pathways in fruit flies could offer new clues about alcohol tolerance in humans, Dr. Montooth added. She and University of Chicago researcher Mohammad A. Siddiq conducted experiments with living transgenetic flies in her Lincoln laboratory during October 2015. They found the ADH amino acid changes made no discernible difference in the species' ability to survive while being fed increasingly heavy doses of alcohol. The flies had been genetically engineered by University of Wisconsin-Madison researcher David Loehlin, Ph.D., so that their only genetic difference was in the ADH protein sequence.

The experiments with living fruit flies supported the findings of other experiments investigating the enzyme's biochemistry. With molecular evolution, scientists seek to identify the specific molecular changes underlying the trait changes that shape the evolutionary family tree.

“We're generating so much sequence data right now, from so many species, that it's relatively straightforward to look for signatures of selection in genes and to find good candidates for adaptations,” Dr. Montooth said. “But those are just candidates. You have to test them functionally if you want to say those are the variants favored by natural selection.”

Siddiq and Dr. Montooth began working together in 2008 after Siddiq took the freshman biology course Dr. Montooth taught while on faculty at Indiana University. He began working in her laboratory and co-authored research with her while he was an undergraduate student.

“Despite now being in my fifth year of graduate school, I'm still publishing papers with the professor that I met on my first day of college,” Siddiq said.

Siddiq, who is the study's first author, is now pursuing a doctoral degree at the University of Chicago, where he is studying with co-author Joseph W. Thornton, Ph.D., a professor who studies the molecular mechanisms of evolution. Dr. Loehlin, a postdoctoral researcher at the University of Wisconsin–Madison, also participated in the study, creating the transgenic flies used in the experiments. He came to Lincoln to work with Dr. Montooth on the fruit fly study, he said, because of her experience and expertise in evolutionary physiology and because of her influence on his career.

“I took her introductory biology class (as a college freshman) and loved it because her passion for evolution and its role as a unifying principle in biology really came through,” Siddiq said. “My appreciation for studying traits not only in the test tube, but in the level of organisms, comes from the experiments I did during my undergraduate years.”

The new study is the first demonstration of an approach combining ancestral sequence reconstruction with the making of transgenic organisms to test hypotheses directly at multiple biological levels, Siddiq pointed out. It's a broadly applicable approach that in theory could be used with other organisms that lend themselves to transgenic engineering.

“One of the neat things about this paper is that it looks at the effects of this gene's mutations at the level of how the enzyme functions in the test tube, how it functions in the fly, and then the consequences for how the fly deals with ethanol,” explained Dr. Montooth. “It's looking at effects of mutations across different levels of biological organization. Each of the co-authors played a role by investigating a different level of organization.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →